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Background: Chronic lung diseases are marked by progressive inflammation, tissue damage and remodelling. Bone
marrow-derived progenitor cells may contribute to these processes. The objectives of this study were to (1) to
quantify CD45+Collagen-1+ fibrocytes and a novel epithelial-like population of bone marrow-derived cells, which
express Clara Cell Secretory Protein, in patients at the time of lung transplant and (2) to evaluate mediators that
may act to recruit these cells during injury.
Methods: Using an observational design, progenitor cells were quantified by flow cytometry from both bone
marrow (BM) and peripheral blood (PB). Migration was tested using in vitro transwell assays. Multiplex bead-based
assays were used to quantify plasma cytokines.
Results: An increase in CD45+Collagen-1+ fibrocytes was found in pulmonary fibrosis and bronchiolitis obliterans
patients. Cystic fibrosis patients had an increase in CCSP+ cells in both the BM and PB. The proportion of CCSP+
cells in the BM and PB was correlated. CCSP+ cells express the chemokine receptors CCR2, CCR4, CXCR3, and
CXCR4, and significantly migrated in vitro toward Stromal Derived Factor-1 (SDF-1) and Stem Cell Growth Factor-β
(SCGF-β). Plasma cytokine levels differed between disease groups, with a significant correlation between SCGF-β
and CCSP+ cells and between Monocyte Chemotactic Protein-1 and fibrocytes.
Conclusions: Different bone marrow-derived cells are found in various lung diseases. Increased fibrocytes were
associated with fibrotic lung diseases. An increase in the novel CCSP+ epithelial-like progenitors in cystic fibrosis
patients was found. These differences may be mediated by alterations in plasma cytokines responsible for cell
recruitment.
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Many pulmonary pathologies including cystic fibrosis
(CF), pulmonary fibrosis (PF), chronic obstructive pul-
monary disease (COPD), and pulmonary hypertension
(PH) follow a progressive course, and at their end stages
are treatable only by transplantation [1]. Taken together,
features of chronic lung diseases commonly include ex-
cessive inflammation, tissue remodelling, and epithelial
damage, which ultimately leads to a loss of function and
organ failure [2,3].* Correspondence: tom.waddell@uhn.on.ca
1Latner Thoracic Surgery Research Laboratories, Division of Thoracic Surgery,
Toronto General Hospital, University Health Network, University of Toronto,
North Wing, 9N - 949, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
Full list of author information is available at the end of the article
© 2013 Gilpin et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe contribution of bone marrow-derived cell popula-
tions to adult tissue repair has been widely studied, and
although controversial, evidence exists implicating vari-
ous progenitor populations in both tissue remodelling,
pathogenic fibrosis, and productive repair. Numerous in-
vestigators have described therapeutic benefits with ex-
ogenously applied marrow-derived populations [4-6],
however the endogenous role of such populations is
uncertain [7]. In the context of human chronic lung dis-
ease, we chose to investigate two bone marrow-derived
populations to determine the numbers of these cells in
various disease states.
We have previously described a novel epithelial-like
progenitor population marked by Clara Cell Secretory
Protein (CCSP) found within the bone marrow (BM)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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induced lung injury in mice, a transient increase in bone
marrow and peripheral blood CCSP+ cells was measured
following injury. In addition, when labelled CCSP+ cells
were delivered (trans-tracheally or intravenously), injured
murine lungs were found to were found preferentially re-
tain CCSP+ as compared to CCSP- cells. For these reasons,
it was hypothesized that CCSP+ epithelial-like progenitor
cells may also be important in human lung disease.
In addition, circulating CD45+Collagen-1+ fibrocytes
have also been implicated in the development of tissue
fibrosis, in both animal models and human disease.
Inhibition of this cell population though blockage of
SDF-1/CXCR4-mediated migration has been shown to
attenuate bleomycin-induced lung injury in mice [9].
Quantification of circulating fibrocyte numbers has also
been shown to be an independent predictor of survival
in pulmonary fibrosis patients [10], and we recently
reported an increase in this population in patients with
bronchiolitis obliterans [11].
These two populations have not previously been com-
pared across disease groups and taken together may play
an important role in disease pathology. This study aimed
to quantify both cell populations in the bone marrow
and/or peripheral blood of end-stage lung disease patient
at the time of transplantation. We hypothesise that a
specific relationship may exist between the number and
recruitment ability of specific bone marrow-derived cell
populations and specific end-stage lung disease patholo-
gies. Utilizing an observational study design we aimed to
investigate these relationships across various end-stage
lung diseases. Investigation of plasma cytokine mediators
of cell mobilization or trafficking also aimed to elucidate
key differences in these factors between disease groups
and in relation to progenitor cell numbers.
Methods
The study was designed with a cross-sectional, observa-
tional approach and was approved by the University
Health Network Research Ethics Board (#07-0598TE).
Written informed consent was obtained from all sub-
jects. The study population consisted of lung transplant
recipients at the Toronto General Hospital between Nov
2007 and Jan 2011. Lung donors were also included as a
comparison group.
Sample preparation
Bone marrow (BM) was obtained from the exposed ster-
num and prepared by Ficoll. Equal parts heparinized
peripheral blood (10 ml) were prepared by Ficoll isola-
tion for peripheral blood mononuclear cells (PBMCs),
which was used for CCSP cell quantification, and by
high-speed centrifugation for peripheral blood leuko-
cytes (PBLs), which was used for fibrocyte quantification.PBLs were treated with red cell lysis buffer. Plasma was
collected from the centrifuged aliquot.
Flow cytometry
For CCSP+ cell quantification, freshly isolated BMCs
and PBMCs were blocked with 10% goat serum and 10%
Fc Block (Miltenyi Biotech), stained with rabbit anti-
mouse/human CCSP (1:200; Upstate Labs) or IgG
control antibody (R&D), followed by Alexa Fluor 488
secondary (1:1000; Invitrogen).
For fibrocyte quantification, freshly isolated PBLs we
blocked as above, stained with mouse anti-human CD45
(1:5: PerCP-conjugated, BD Biosciences), permeabilizied
using Cytoperm solution (BD Biosciences), and subse-
quently stained with rabbit-anti-human collagen type-1
(1:100; Rockland Immunochemicals) or IgG control anti-
body, followed by AlexaFluor 488 secondary (1:1000;
Invitrogen). For double-staining experiments, CCSP anti-
body was detected with an AlexaFluor 647 secondary
(Invitrogen) and the chemokine receptors detected with
PE-conjugated antibodies (BD Biosciences), providing suf-
ficient spectral emission separation.
All data was generated using a Coulter Cytomics
FC500 analyzer, collecting 20,000 events per sample, and
analyzed with FlowJo software. Sorting of isolated CCSP
+ peripheral bloods cells for PCR was performed on a
BD FACSAria II, starting with 60 ml of peripheral blood
from a healthy, male volunteer.
Real-time PCR
Real-time quantitative PCR was performed by Taqman
technology (Applied Biosystems). In brief, total RNA
was isolated using the RNeasy Kit (Qiagen) and RNA con-
centrations were determined by Nanodrop analyzer
(Thermo Scientific). First-strand cDNA was generated
using Superscript III (Sigma) protocol. Real-time PCR was
performed for amplification of the CCSP or Collagen-1
gene products (Taqman probes Hs00171092_m1 and
Hs00164004_m1). Beta-2-Microglobulin was used as en-
dogenous control (Applied Biosystems; 4333766 T). Hu-
man bronchus tissue (positive control) was collected from
explanted recipient lungs, subject to collagenase digestion
(Stem Cell Technologies), and prepared in parallel. Con-
trol RNA samples not subjected to reverse transcription
(NRT) and water (no template, NTC) were used as nega-
tive controls.
In vitro transwell migration assays
Migration of CCSP+ cells was assessed in response to
chemotactic stimuli in healthy subjects (median age =
29 yrs, M:F = 6:3) vs. transplant recipients (median age =
45.5, M:F = 9:7). Initially, 1 × 106 BMCs or PBMCs were
layered onto a 5 μm-pore membrane insert and placed into
contact with DMEM+ 10% FBS + the cytokine Regulated
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(RANTES) 20 ng/ml, Interferon gamma-induced Protein
10 (IP-10) 25 ng/ml, Stromal-Derived Factor −1 (SDF-1)
10 ng/ml, or Stem Cell Growth Factor-β (SCGF-β) 5 ng/
ml; Peprotech) in a 24-well tissue culture plate (Costar).
Following 2 hours of migration all cells recovered in the
lower chamber were collected, counted, and analyzed for
CCSP expression by flow cytometry. Migrated CCSP+ cells
were determined as follows:
Total cells migrated  % CCSPþ
¼ Absolute CCSPþ cells migrated ð1Þ
Absolute CCSPþ migrated to chemokine=Absolute




Plasma samples were analyzed by Luminex-based
multiplex array (BioRad Bio-Plex System) according to
manufacturer protocols. Targets analyzed are listed in
Additional file 1: Table S3. Bio-Plex Manager software
was used for data acquisition.
Statistics
Statistical analysis was performed using GraphPad Prism
software. Data are presented as median ± range, with
whiskers encompassing the 5-95th percentiles. Normal-
ity was tested using the D’Agostino & Pearson omnibus
test and non-parametric tests were used throughout. A
Mann–Whitney test was used for comparison of non-
parametric variables between two groups. Multiple
comparisons were made using a Kruskal-Wallis test
with Dunn’s multiple comparison post-test correction.
Spearman rank test with correlation coefficient was
used to determine relationships between two variables.
Statistical significance was defined as p < 0.05.
Results
Identification of progenitor populations in end-stage lung
disease patients
Circulating bone marrow-derived cell populations were
defined by (1) Clara Cell Secretory Protein (CCSP) expres-
sion for epithelial-like progenitors and by (2) dual expres-
sion of CD45 and intracellular collagen-1 expression for
fibrocytes. To validate the expression of CCSP mRNA in
the bone marrow and peripheral blood, Taqman PCR was
utilized. CCSP mRNA was detected in human bone mar-
row cells (BMCs) and peripheral blood mononuclear cells
(PBMCs) from 3 randomly selected lung transplant recipi-
ents, as well as in control lung bronchus tissue, but absentin experimental controls (no reverse transcription and
no template controls) (Figure 1A-B). As a further proof-
of-principle, peripheral blood cells from a healthy volun-
teer were isolated and sorted for CCSP by flow cytometery,
representing less than 1% of total PBMCs, and then ana-
lyzed by PCR. CCSP mRNA was also detected in the pre-
sorted population but not in CCSP-negative sorted cells
(Figure 1C). The resulting amplification product was fur-
ther analyzed by gel electrophoresis to confirm the correct
amplicon size (Figure 1D), and compared to positive hu-
man bronchus tissue mRNA and a mixture of sample
mRNAs not subjected to reverse transcription (NRT) to
control for genomic DNA contamination. All subsequent
quantification of progenitor cells populations was deter-
mined by flow cytometry. A representative plot identify-
ing the positively gated populations based on initial
isotype staining of 1% is shown for both CCSP+ cells
and CD45+Collagen-1+ fibrocytes (Figure 1E-F). Further
details of the gating strategy have been previously
published [11].
Bone marrow and peripheral blood samples were col-
lected from patients at the time of lung transplant (n =
154). A summary of relevant lung recipient demographics,
including age, gender, diagnosis, diabetes status, BMI, and
graft number is presented in Table 1. In addition, blood
and bone marrow samples were obtained from lung do-
nors prior to organ recovery (n = 36), the details of which
are summarised in Table 2. For logistical reasons, not
every patient undergoing lung transplantation or donor
procurement could be analyzed in this study. A compari-
son of recipient and donor demographics from patients
included in this analysis compared to the demographics of
all those transplanted at our centre in the same time
period identified no significant differences in these param-
eters (Additional file 2: Table S1 and Additional file 3:
Table S2).
No significant relationships were identified when these
progenitor cell populations were analysed by age, gender,
or BMI (data not shown). There were significant differ-
ences in the proportion of bone marrow-derived cells
populations based on underlying lung disease. An in-
crease in the proportion of CCSP+ cells was found in the
bone marrow of CF patients when compared to lung do-
nors (CF median = 1.33%, Donor median = 0.98, p < 0.05)
(Figure 2A). We chose to use lung transplant donors as
a comparison group as we had access to sternal marrow
biopsy material obtained using identical collection tech-
niques, not easily obtained in any other way. Different
cell proportions were also found for CCSP+ cells in the
peripheral blood. Specifically, CF patients had a greater
proportion of CCSP+ cells when compared to lung
donors (2.28% CF vs. 1.90% Donor, p < 0.05) (Figure 1B),
while BO patients had a significantly lower proportion
of CCSP+ PBMCs compared to donors (0.55% vs. 1.90%
Figure 1 Identification of progenitor populations. Taqman PCR measurement of (A) Clara Cell Secretory Protein (CCSP) gene expression in
human bone marrow cells (BMCs), (B) peripheral blood mononuclear cells (PBMCs), and (C) PBMCs pre-sorted for CCSP by flow cytometry. No
template and no reverse transcription negative controls are included. (D) Gel electrophoresis of PCR product after Taqman-based amplification.
Positive control (bronchus) and negative no reverse transcription (NRT) controls are included. (E) Flow cytometry gating for measurement of
CCSP+ PBMCs based on isotype control staining. (F) Flow cytometry gating for measurement of CD45+Collagen-1+ peripheral blood leukocytes
(PBLs) based on isotype control staining.
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fibrocytes were compared between disease groups, an in-
creased proportion was found in both BO patients (p <
0.001) and PF (p < 0.05) patients, when compared to Do-
nors (Median BO = 7.02%, Median PF = 2.07%, Median
Donors = 0.85%) (Figure 2C). As the changes in cell
numbers appeared to reciprocal, the ratio of fibrocytes-
to-CCSP+ PBMCs was calculated, and a similar pattern
was found, where a predominantly fibrotic phenotype isrepresented in BO and PF, but not in other lung path-
ologies (Figure 2D).
In order to determine if the proportion of CCSP+ cells
was reflective of the total number of CCSP+ cells, the ab-
solute cell numbers were determined using total leukocyte
counts collected from clinical data (109/L). When absolute
cell numbers were compared, the differences in progenitor
cell numbers between disease groups were still statistically
significant (Additional file 4: Figure S1).




















PPH + Eisenmenger’s +
Congenital Abnormalities
14 (9.1)
Retransplant + BO 6 (3.9)
Other 5 (3.2)
Diabetes mellitus
Non-Insulin Dependent 17 (11.0)
Insulin Dependent 20 (13.0)
No Diabetes 117 (76.0)




Table 2 Demographics of lung donors sampled
All donors sampled
(n = 36)











Primary CNS Tumor 1 (2.8)




No Diabetes 34 (94.4)
BMI, mean (SD, kg/m2 25.6 ± 4.9
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within the bone marrow and the proportion in the per-
ipheral blood, data was analyzed including all disease
groups together. A significant correlation was found be-
tween the number of bone marrow and peripheral blood
CCSP+ cells (Figure 3A). In contrast, no relationship was
found between the number of fibrocytes and either
CCSP+ BMC or PBMCs (Figure 3B-C).
Analysis of clinical disease indicators relative to pro-
genitor cell numbers was done using spirometric lung
function values, using the ratio of the forced expiratory
volume in 1 second (FEV1) to forced vital capacity
(FVC) (FEV1/FVC) ratio for CF and COPD patients, or
based on the percentage of predicted FVC for PF pa-
tients. No direct relationships were found between lung
function measurements when compared with the total
number of epithelial-like progenitors in the bone mar-
row or peripheral blood or with circulating fibrocytes
(Figure 4A-I).
In order to further investigate the biology of these cell
populations in end-stage lung disease patients, we nextanalyzed the potential role of receptor-mediated cytokine-
induced migration of CCSP+ cells.Mechanisms of CCSP+ progenitor cell recruitment
In order to explore possible mechanisms of recruitment
of these cells chemokine receptor expression was investi-
gated for several chemokines implicated in the literature.
Chemokine receptor expression by CCSP+ epithelial-like
progenitor cells was first examined by flow cytometry.
Sub-populations of CCSP+ BMC and PBMCs were iden-
tified that co-express CCR2, CCR4, CXCR3, or CXCR4
(Figure 5A-D).
To further investigate the ability of CCSP+ cells to mi-
grate in response to chemotactic mediators, in vitro
transwell assays were utilized. Migration of bone marrow
or peripheral blood cells (BMCs) freshly isolated from
end-stage lung disease patients was investigated in re-
sponse to the chemotactic stimuli RANTES, IP-10, SDF-
1, or SCGF-β and compared to untreated cells (Figure 6).
A significant migratory response of CCSP+ cells toward
SDF-1 was identified for CCSP+ PBMCs from control
and lung recipient samples, as well as from BMCs from
lung recipients, compared to untreated cells in the ab-
sence of any chemotactic stimuli. In addition, significant
migration in response to SCGF-β was also found for
CCSP+ BMCs and PBMCs isolated from end-stage lung
disease patients (p < 0.05), while no significant migratory
response was found for CCSP+ PBMCs isolated from
healthy controls (Figure 6).
Figure 2 Differential progenitor cell profiles in end-stage lung disease patients. (A) Percentage of bone marrow cells (BMCs) positive for
CCSP in each disease group (n = 26 donor, n = 5 Bronchiolitis Obliterans (BO), n = 27 Cystic Fibrosis (CF), n = 34 Chronic Obstructive Pulmonary
Disease (COPD), n = 41 Pulmonary Fibrosis (PF), n = 11 Pulmonary Hypertension (PH)). (B) Percentage of peripheral blood mononuclear cells
(PBMCs) positive for CCSP in each disease group. (n = 29 donor, n = 6 BO, n = 33 CF, n = 41 COPD, n = 53 PF, n = 13 PH). (C) Percentage of
peripheral blood leukocytes (PBLs) positive for CD45 and collagen-1 in each disease group (n = 17 donor, n = 6 BO, n = 14 CF, n = 22 COPD, n =
26 PF, n = 8 PH). (D) Ratio of CCSP+ PBMCs to CD45+collagen-1+ fibrocytes in each disease group, compared to lung donors (n = 13 donor, n = 6
BO, n = 10 CF, n = 17 COPD, n = 18 PF, n = 8 PH). Kruskal-Wallis test with Dunn’s multiple comparison post-hoc analysis. Boxes show the median,
25th and 75th percentiles. Whiskers represent the 2.5 and 97.5 percentiles.
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ment mediators, a multiplex array was performed on a
subset of end-stage lung disease patients’ plasma. A total
of 17 targets were selected based on biological action and
quantified simultaneously (see methods and Additional
file 1: Table S3). These results were then analyzed in rela-
tion to progenitor cell numbers.
When the plasma protein concentrations were com-
pared across the 3 main end-stage lung diseases, differ-
ent patterns of expression were noted for some key
inflammatory cytokines. Specifically, it was found that
IP-10 and MCP-1 are increased in IPF patients, while
MIG is increased in across all 3 end-stage groups, and
MIF is specifically increased in CF patients when each
were compared to lung donor and healthy volunteer
control plasma (Figure 7A-D).
To further investigate the function of plasma protein
mediators in progenitor cell recruitment, the relation-
ship between protein concentration and cell numbers
was analyzed. The number of CCSP+ cells in the bone
marrow and peripheral blood significantly correlated with
the plasma concentration of Stem Cell Growth Factor-
beta SCGF-β (Figure 8A) in a range of samples, including
lung transplant recipients, donors, and control samples. Inaddition, it was further found that fibrocyte numbers
correlated with the plasma concentration of MCP-1
(Figure 8B).
Discussion
The results presented demonstrate a relationship be-
tween the profile of putative lung progenitor cell popula-
tions and chronic lung diseases. Specific relationships
between increased CCSP+ epithelial-like progenitors and
cystic fibrosis and between increased circulating fibrocytes
and fibrotic diseases such as pulmonary fibrosis and bron-
chiolitis obliterans were identified. Furthermore, the results
suggest the involvement of key chemotactic mediators, in-
cluding SDF-1, SCGF-β, and MCP-1 in the recruitment or
maintenance of these cell populations within the specific
disease groups studied.
In our previous publication [8] we reported that mur-
ine bone marrow contains a population of cells which
express CCSP on their surface. This was confirmed by
PCR on FACS-sorted populations, western blotting, and
with the use of CCSP knockout mice. This population
demonstrated a greater propensity to express a lung
epithelial phenotype at the gene and protein level and
was preferentially retained in injured lung, compared to
Figure 3 Relationship between progenitor cell populations. (A) Correlation between the percentage of Clara Cell Secretory Protein (CCSP+)
Peripheral Blood Mononuclear Cells (PBMCs) and CCSP+ Bone Marrow Cells (BMCs) (n = 119 pairs). (B) Lack of correlation between the percentage
of CD45+Collagen-1+ fibrocytes and CCSP+ BMCs (n = 59 pairs). (C) Lack of correlation between the percentage of CD45+Collagen-1+ fibrocytes
and CCSP+ PBMC (n = 74 pairs). Spearman rank test with correlation coefficient.
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lial lining after bone marrow transplantation. As a result
of these properties, we termed these cells epithelial-like
progenitor cells. We also reported that human marrow
contains a similar population by flow cytometry. Here
we confirm that human bone marrow and peripheral
blood contain such cells using specific Taqman-based
PCR probes. Of note, the amount of CCSP mRNA is
roughly 60 fold lower than bronchial tissues, but many
fold higher than other types of bone marrow cells.
The assessment of both epithelial-like and fibroblast
progenitor cell populations in chronic end-stage lung
disease patients has not been previously reported. We
hypothesized that when studying such variable diseases,
the measurement of two cell populations with potentially
contradictory functions would provide a more complete
understanding. Indeed, there are significant differences in
these cell populations when compared between underlying
diseases. Specifically, CCSP+ cells in the bone marrow and
peripheral blood were increased in CF patients where small
airway epithelial damage and injury may be a predominant
and persisting stimulus. Acknowledging the differences be-
tween acute and chronic lung injury, and between mouse
and human studies, these findings support our original ob-
servations in mice where these cells increased following an
epithelial-specific naphthalene-induced airway injury. We
speculate that this may be attributable to a sustained butunresolved effort to repair the damaged CF epithelium
leading to a persistent inflammatory environment resulting
in a perpetual recruitment signal to the bone marrow
and accumulation of the CCSP+ epithelial-like progeni-
tor population. It has previously been reported that
bronchial epithelium from CF patients is more prolifer-
ative than that from non-CF airways [12]. Humanized
airway xenografts, where CF-derived cells portrayed a
greater proliferative potential, were further character-
ized by remodelling, delayed differentiation, and altered
pro-inflammatory responses [13].
The observation that circulating fibrocytes are in-
creased in fibrotic diseases is in agreement with prior
evidence [10,14]. We also have documented that BO pa-
tients are a particularly striking subset in terms of very
high numbers of fibrocytes [11]. This supports the hy-
pothesis that circulating fibrocytes can contribute to the
lung fibroblast population, either through paracrine acti-
vation of endogenous fibroblasts or by engraftment and
direct contribution to matrix deposition and remodelling.
The measurement of both epithelial and mesenchymal
progenitor populations has identified changes in these cell
numbers that correspond with changes in the underlying
epithelial or mesenchymal lung pathology. Specifically, in-
creased epithelial-like progenitors were identified in CF
where the epithelium is hyperplastic, whereas mesenchy-
mal progenitors were increased in disease characterized
Figure 4 Lung function and progenitor cell profiles. No correlation in Cystic Fibrosis (CF) patients between FEV1/FVC and (A) Clara Cell
Secretory Protein (CCSP+) bone marrow cells (BMCs) (n = 27), (B) CCSP + peripheral blood mononuclear cells (PBMCs) (n = 32), or (C) CD45 +
Collagen-1+ fibrocytes (n = 14). No correlation in Chronic Obstructive Pulmonary Disease (COPD) patients between FEV1/FVC and (D) CCSP +
BMCs (n = 34), (E) CCSP + PBMCs (n = 40), or (F) CD45 + Collagen-1+ fibrocytes (n = 22). No correlation in Pulmonary Fibrosis (PF) patients
between the measured percentage of predicted of FVC and (G) CCSP + BMCs (n = 41), (H) CCSP + PBMCs (n = 53), or (I) CD45 + Collagen-1+
fibrocytes (n = 26). Spearman rank test.
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nisms exist in end-stage lung disease patients, the unique
biology of CF versus fibrotic lung disease may be further
described by these novel differences in progenitor cells
numbers, opening up new avenues of investigation.
Importantly, no correlations were found between patient
age, gender, or BMI, suggesting that these demographic
parameters do not seem to influence the observed changes
in cell profiles. Yet a correlation between the proportion
of CCSP+ BMCs and PBMCs was identified, suggesting a
relationship between number of bone marrow cells in re-
serve and the number that can exit and traffic through
peripheral blood. SCGF-β was found to correlate signifi-
cantly with the number of both CCSP+ cell populations. It
is possible that SCGF-β may act as an endogenous mito-
gen for the epithelial-like progenitors, as have been de-
scribed for CD34+ hematopoietic cells [15], although thedirect source of this factor has not been determined in this
study. No correlations were identified between CCSP+ cell
populations and the proportion of circulating fibrocytes.
This suggests that distinct mechanisms may be respon-
sible for the recruitment of each population and argues
against a generalized alteration in marrow-derived cell
mobilization or trafficking.
This study has several limitations, most importantly
the cross-sectional design. Future studies will be needed
to obtain data from patients at various points during the
development of their lung disease. However it is doubt-
ful that sampling of the bone marrow will be possible in
such a longitudinal follow up study. In these patients, all
with severe end-stage lung disease awaiting lung trans-
plantation, there was no significant relationship between
CCSP+ BMCs/PBMCs or CD45+Collagen-1+ cells and
FEV1/FVC ratio in CF or COPD patients or with the %
Figure 5 Chemokine receptor expression by Clara Cell Secretory Protein (CCSP+) Cells. Dual expression of chemokine receptors and Clara
Cell Secretory Protein (CCSP) on bone marrow cells (BMCs) and peripheral blood mononuclear cells (PBMCs). Representative flow plots are based
on PBMCs. (A) CCR2 (B) CCR4 (C) CXCR3 (D) CXCR4. Bars graphs display the mean and standard error.
Figure 6 In vitro migration assay. Migration of freshly isolated
peripheral blood mononuclear cells (PBMCs) or bone marrow cells
(BMCs) in response to chemotactic stimuli Regulated upon
Activation, Normal T-cell Expressed, and Secreted (RANTES) (n = 9
control, 11 recipient PBMC, 7 BMC), Interferon gamma-induced
protein 10 (IP-10) (n = 9 control, 11 recipient PBMC, 7 BMC), Stromal
Derived Factor-1 (SDF-1) (n = 9 control, 13 recipient PBMC, 9 BMC),
or Stem Cell Growth Factor-beta (SCGF-β) (n = 4 control, 4 recipient
PBMC, 4 BMC), compared to untreated cells. Migrated cells were
analyzed for CCSP+ expression and normalized to total CCSP+ cells
in the starting sample. Kruskal-Wallis test with Dunn’s multiple
comparison post-hoc analysis, with significance tested against
untreated samples (* = p < 0.05, ** = p < .01). Boxes show the
median, 25th and 75th percentiles. Whiskers represent the 2.5 and
97.5 percentiles.
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not exclude the possibility that these cell populations
contribute to lung disease pathology, and further analysis
in patients at much earlier stages of the lung disease will
be important future priorities. In addition, many other im-
portant clinical parameters influence pulmonary function
and these confounding variables may have obscured any
relationship between cell numbers and lung function. An-
other limitation is the use of lung donors as a control
group. While not ideal, as this group may well have acute
or chronic damage to the lung, it represented the only op-
tion for analysis of bone marrow as sternal harvest of truly
normal controls would not be ethical.
In an effort to understand the mechanisms responsible
for different progenitor cell profiles between lung diseases,
key chemokines and receptors were analyzed. Fibrocytes
have been previously been reported to express a number
of important chemokine receptors including CXCR4 [9],
CCR2 [16], and CCR7 [17]. When CCSP+ BMCs and
PBMCs were analyzed for a panel of similar receptors, ex-
pression of CCR2, CCR4, CXCR3, and CXCR4 was identi-
fied. It is expected that some pathways are redundant and
some cytokines will have the ability to activate both cell
populations. This is perhaps evidence of the bone marrow
origin of both populations.
Migration studies for CCSP+ were performed to inves-
tigate the in vitro response to various chemokines. Mi-
gration was not analyzed for fibrocytes, as this has been
Figure 7 Plasma cytokine concentrations in end-stage lung disease patients. Comparison of plasma cytokine concentrations between cystic
fibrosis (CF) (n = 19), chronic obstructive pulmonary disease (COPD) (n = 16), and pulmonary fibrosis patients (PF) (n = 17) compared to lung
donor and healthy volunteer controls (n = 18). Statistically significant differences were found for (A) Interferon gamma-induced protein 10 (IP-10),
(B) Monocyte Chemotactic Protein-1 (MCP-1) (C) Monokine-Induced by Gamma Interferon (MIG), and (D) Macrophage Migration Inhibitory Factor
(MIF) levels. Kruskal-Wallis test with Dunn’s multiple comparison post-hoc analysis. Boxes show the median, 25th and 75th percentiles. Whiskers
represent the 2.5 and 97.5 percentiles.
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http://www.biomedcentral.com/1471-2466/13/48previously reported [9,18]. Here, we found that Stromal
Derived Factor (SDF-1) was an important migration
stimulus for CCSP+ cells, as has also been reported for
fibrocytes. It has been previously reported that neutraliz-
ing antibodies against SDF-1 can attenuate the fibrotic
effects of bleomycin-induced mouse lung injury [9].Figure 8 Plasma protein concentration and progenitor cell numbers.
β levels and the percentage of CCSP+ bone marrow cells (BMCs) (n = 44) o
recipients (R) and donors (D), and healthy controls (BMC: n = 35R, 9D. PBMC
Chemotactic Protein (MCP)-1 levels and the percentage of CD45+Collagen-
controls (n = 29R, 6D, 2H). Spearman rank test with correlation coefficient.Pulmonary expression of SDF-1 has also been reported
in the context of lung injury and the recruitment of
bone marrow-derived cells [19]. SCGF-β was also found
to induce migration of CCSP+ PBMCs and BMCs in
end-stage lung disease patients. This supports the ob-
served correlation between this plasma cytokine and the(A) The relationship between plasma Stem Cell Growth Factor (SCGF)-
r CCSP+ peripheral blood mononuclear cells (PBMCs) in lung transplant
: (n = 49R, 9D, 8H). (B) The relationship between plasma Monocyte
1+ fibrocytes in lung transplant recipients and donors, and healthy
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http://www.biomedcentral.com/1471-2466/13/48number of CCSP+ cells measured. Expression of SCGF-
β transcripts is reportedly restricted to cells of the mye-
loid lineage [20], which may include resident lung
macrophages. The expression of CCR2 by both cell
populations, as well as the increase in the ligands IP-10
and MCP-1 in pulmonary fibrosis further highlights the
role of inflammation in many end-stage lung diseases.
The plasma concentration of MCP-1 was further shown
to correlate to the number of circulating fibrocytes,
again identifying a role for CCR2-mediated recruitment
of progenitor cells, which may be enhanced in the
fibrotic patient.
Interestingly, MIF was found to be specifically in-
creased in CF patients, perhaps suggesting a unique
role for CD74 or CXCR4 in the mechanism of CCSP+
cell recruitment. It has been reported that MIF can act
as a ligand for CXCR4 and induce the migration of
monocytes and T-cells, perhaps suggesting a novel
mechanism of epithelial-like progenitor cell trafficking
[21,22]. MIF is a pleiotropic inflammatory mediator
with chemokine-like functions that can direct migration
of leukocytes to inflammatory sites [21]. MIF has also
been shown to be produced by epithelial cells [23] and
activated alveolar macrophages [24], suggesting a po-
tential mechanism by which damaged CF epithelium
recruits circulating CCSP+ cells. Enhancing CCSP+ re-
cruitment using MIF may not be a viable therapeutic
option as MIF acts on multiple cells types and may ex-
acerbate inflammatory responses.
Conclusions
Taken together, this evidence provides new understand-
ing of the pathogenesis of end-stage lung disease, espe-
cially cystic fibrosis. We initially hypothesized that loss
of epithelial-like progenitors may be linked to impaired
epithelial repair in COPD or IPF, but this was not found
in this particular patient set. The association of an
increase in epithelial progenitors and the changes in
proliferative capacity of CF epithelium is surprising and
novel. It remains to be determined if the increase in
epithelial-like progenitor population in bone marrow
and peripheral blood is the cause or consequence of the
epithelial hyperproliferation seen in CF, which, warrants
further exploration. The gain of circulating fibroblastic
progenitors may contribute to the altered tissue repair
and remodelling processes observed in the fibrotic lung.
Alterations in circulating inflammatory and stem cell
recruitment factors are likely an important element in
the control of progenitor cell trafficking and in the
ultimate ability to influence lung tissue repair or path-
ology. Modulation of important factors including MCP-
1, MIF, SCGF-β and/or SDF-1 is likely an important
avenue for further investigation and ultimately thera-
peutic intervention.Additional files
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